BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kan H, Imamura M, Kawakami Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Kobayashi T, Nakahara T. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients. J Med Virol. 2017;89:1963-1972. [PMID: 28657143 DOI: 10.1002/jmv.24885] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Scott LJ. Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. Drugs 2018;78:245-56. [DOI: 10.1007/s40265-018-0864-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
2 Othumpangat S, Noti JD. Antiviral Drugs. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Elsevier; 2018. pp. 345-61. [DOI: 10.1016/bs.seda.2018.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G, Aumaitre H, Alric L, Boué F, Morlat P, Poizot-Martin I, Billaud E, Rosenthal E, Naqvi A, Miailhes P, Bani-Sadr F, Esterle L, Carrieri P, Dabis F, Sogni P, Wittkop L, ANRS CO13 Hepavih study Group. Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients. World J Hepatol 2018; 10(11): 856-866 [PMID: 30533186 DOI: 10.4254/wjh.v10.i11.856] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Aldunate F, Echeverría N, Chiodi D, López P, Sánchez-Cicerón A, Soñora M, Cristina J, Moratorio G, Hernández N, Moreno P. Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report. BMC Infect Dis 2021;21:387. [PMID: 33902462 DOI: 10.1186/s12879-021-06080-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Saito Y, Imamura M, Uchida T, Osawa M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Serikawa M, Aikata H, Abe-Chayama H, Hayes CN, Chayama K. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy. J Med Virol 2020;92:210-8. [PMID: 31584207 DOI: 10.1002/jmv.25602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Wang YW, Lee WP, Huang YH, Hou MC, Lan KH. Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis. BMC Infect Dis 2021;21:984. [PMID: 34548026 DOI: 10.1186/s12879-021-06657-9] [Reference Citation Analysis]
7 Morio K, Imamura M, Kawakami Y, Nakamura Y, Hatooka M, Morio R, Fujino H, Nakahara T, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Miki D, Ochi H, Katamura Y, Arataki K, Moriya T, Ito H, Tsuji K, Kohno H, Waki K, Tamura T, Nakamura T, Chayama K; Hiroshima Liver Study Group. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C. J Med Virol 2018;90:1834-40. [PMID: 30016555 DOI: 10.1002/jmv.25267] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Teraoka Y, Uchida T, Imamura M, Hiraga N, Osawa M, Kan H, Saito Y, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure. J Gen Virol 2018;99:1058-65. [PMID: 29916799 DOI: 10.1099/jgv.0.001091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
9 Barriocanal M, Fortes P. Long Non-coding RNAs in Hepatitis C Virus-Infected Cells. Front Microbiol. 2017;8:1833. [PMID: 29033906 DOI: 10.3389/fmicb.2017.01833] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
10 Jin CN, Chen JD, Sheng JF. Vitamin D deficiency in hepatitis C virus infection: what is old? what is new? Eur J Gastroenterol Hepatol 2018;30:741-6. [PMID: 29664746 DOI: 10.1097/MEG.0000000000001134] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]